Carbon Monoxide Diffusion Capacity as a Severity Marker in Pulmonary Hypertension

Figures

• 

  Figure 1. Flow chart of inclusion and exclusion criteria of the study. Abbreviations: RHC, right heart catheterisation; PH, pulmonary hypertension; PFT, pulmonary functional testing; DLCOc, carbon monoxide diffusing capacity.

• 

  Figure 2. Correlation between (A). DLCOc and 6MWT distance (r = 0.288, p = 0.013) and (B). DLCOc and NT-proBNP (r = −0.222, p = 0.048). Abbreviations: DLCOc, carbon monoxide diffusing capacity; 6MWT, 6-min walk test; NT-proBNP, N-terminal pro-brain natriuretic peptide.

• 

  Figure 3. Kaplan–Meier analysis for DLCOc < 55% and transplant-free survival (A). in all patients (N = 85) (log rank p = 0.002) and (B). in intermediate and high-risk category patients (N = 63) (log-rank p = 0.002).

• 

  Figure 4. Area under the curve (AUC) for transplant-free survival probability over 3- and 5-year follow-up, in intermediate- and high-risk category patients, using the COMPERA and the modified-risk stratification strategy. (A). Five-year transplant-free survival probability with the COMPERA risk: AUC 0.640, Standard error (SE) 0.116, 95% confident interval (CI) 0.487–0.775 and with the modified-risk stratification strategy: AUC 0.711, SE 0.111, 95% CI 0.561–0.834. (B). five-year transplant-free survival probability with the COMPERA risk: AUC 0.710, SE 0.096, 95% CI 0.520–0.858 and with the modified-risk stratification strategy: AUC 0.760, SE 0.091, 95% CI 0.579–0.898.

• 

  Figure 5. Kaplan–Meier analysis for transplant-free survival and (A). 4-strata risk assessment model (log rank p = 0.119) and (B). modified-4-strata risk assessment model (log rank p = 0.002).